Baxter Announces CE Mark and Regulatory Approval of New Evo IQ Infusion System for the United Kingdom, Ireland, Australia and New Zealand

Baxter International Inc. (NYSE:BAX), a leader in innovative technology
for medication delivery, today announced the CE marking of the Evo IQ Infusion
System. In addition to the planned marketing of the device in the United
Kingdom, Ireland and New Zealand, the Evo IQ Infusion System
recently received regulatory approval by the Therapeutic Goods
Administration (TGA) in Australia. These markets represent the first in
a series of planned regulatory submissions for the Evo IQ
Infusion System in countries around the world, with commercial launch
activities starting in the third quarter of 2018.

The Evo IQ Infusion System features a scalable platform and
user-centric design that includes an advanced drug library and dose
error reduction software to promote patient safety; intuitive clinical
workflows to help optimize clinician efficiency; and Baxter’s One Set
technology, which allows clinicians to easily switch between gravity and
pump applications without changing sets, reducing disconnects and set
changes and may help reduce opportunities for touch contamination, along
with helping to reduce IV tubing use and costs.

“With the Evo IQ Infusion System, Baxter is extending its
leading-edge infusion systems technology to help increase drug library
compliance and protect patient infusions in the UK, Ireland, Australia,
and New Zealand,” said David Ferguson, general manager, Medication
Delivery, Baxter. “The Evo IQ Infusion System provides healthcare
facilities with access to Baxter’s proven infusion safety technology in
an adaptable system that can grow with their needs.”

Designed to Promote Patient Safety through Drug Library Compliance

Drug libraries are the defining feature of smart pumps, designed to help
clinicians identify infusion pump programming errors. The drug library
allows hospitals to curate a list of medications and fluids and set
medically appropriate dose ranges. If programming goes beyond the limits
specified for that medication, smart infusion pumps—like the Evo IQ
Infusion System—will alert clinicians before they administer the
medication and in some cases, prevent the delivery of the medication.

Every Evo IQ Infusion System works with Baxter’s customizable Dose
IQ safety software to streamline programming steps and help reduce
the chance of error and is designed to facilitate effective use of drug
libraries, including:

Engineered to Provide a High Standard of Efficiency

At launch, the Evo IQ Infusion System will include a large
volumetric infusion pump, with a pipeline of complementary technology to
launch in the future, including additional pump and set offerings that
will enable healthcare facilities to expand and upgrade the Evo IQ
platform. Other Evo IQ Infusion System features designed to help
increase hospital efficiency include:

For more information on the Evo IQ Infusion System, please visit

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading
portfolio of critical care, nutrition, renal, hospital and surgical
products. For more than 85 years, we’ve been operating at the critical
intersection where innovations that save and sustain lives meet the
healthcare providers that make it happen. With products, technologies
and therapies available in more than 100 countries, Baxter’s employees
worldwide are now building upon the company’s rich heritage of medical
breakthroughs to advance the next generation of transformative
healthcare innovations. To learn more, visit and
follow us on Twitter, LinkedIn and Facebook.

For safe and proper use of this device, refer to the full Instructions
for Use.

This release includes forward-looking statements concerning Baxter’s
Evo IQ Infusion System and Dose IQ Safety Software, including potential
benefits associated with their use. The statements are based on
assumptions about many important factors, including the following, which
could cause actual results to differ materially from those in the
forward-looking statements: satisfaction of regulatory and other
requirements; actions of regulatory bodies and other governmental
authorities; product quality, manufacturing or supply, or patient safety
issues; changes in law and regulations; and other risks identified in
Baxter’s most recent filing on Form 10-K and other SEC filings, all of
which are available on Baxter’s website. Baxter does not undertake to
update its forward-looking statements.

Baxter, Evo IQ and Dose IQ are registered trademarks of Baxter
International Inc.

View source version on

Leave a Comment

Your email address will not be published. Required fields are marked *